Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

Abstract Background Poly (ADP-ribose) polymerase inhibitors (PARPi) prevent single-stranded DNA repair. Olaparib is a PARPi approved for the treatment of BRCA mutant ovarian and breast carcinoma. Emerging clinical data suggest a benefit of combining olaparib with immunotherapy in prostate cancer pat...

Full description

Bibliographic Details
Main Authors: Kathleen E. Fenerty, Michelle Padget, Benjamin Wolfson, Sofia R. Gameiro, Zhen Su, John H. Lee, Shahrooz Rabizadeh, Patrick Soon-Shiong, James W. Hodge
Format: Article
Language:English
Published: BMJ Publishing Group 2018-11-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
PARP inhibitors
ADCC
Prostate carcinoma
BRCA
TRAIL
Online Access:http://link.springer.com/article/10.1186/s40425-018-0445-4

Internet

http://link.springer.com/article/10.1186/s40425-018-0445-4

Similar Items